Our Team

Board of Directors

Kane Black | CEO and Member, Board of Directors

 

Kane Black is Chief Executive Officer and Co-Founder of Nova Satra. Mr Black began his career with Tokyo Stock Exchange-listed technology company, Adtec Corporation K.K., serving as Director and Head of Operations for Europe. He was also instrumental in the buyout of Adtec Corporation by Japanese technology company Shinden Hightex Corporation and remained a Director with the company, based in Europe.

 

In 2012, he co-founded Nova Satra Health to leverage the latest developments in medical technologies with a view to developing, collaborating and commercialising these cutting-edge therapies across the med tech spectrum.

 

He has extensive and diverse international experience in senior roles and entrepreneurial ventures across industries including trading, construction, investment management and biotechnology in Australia, Europe, the Middle East and Asia.

 

Mr Black obtained a Bachelor of International Business from Griffith University and a Bachelor of Business Administration from Bond University, Australia.

Shane Glynn | Finance Director

 

Shane Glynn is Finance Director of Nova Satra. Before joining the company, Mr Glynn was Senior Financial Analyst and Investor Relations Director for Aureos Capital, an asset management firm with US $1.3 Billion AUM. Previously, Mr Glynn served as Senior Manager of Investor Relations at the Royal Bank of Scotland Group where he was the lead investor relations representative for the Group, maintaining extensive relationships with institutional investors and research analysts. Prior to this Mr Glynn had extensive experience as a financial accountant with The National Australia Bank, one of Australia’s largest banks and Australia’s largest telecommunications provider, Telstra Corporation.

 

Mr Glynn is a Chartered Accountant and holds a Bachelor of Commerce with Honours from the University of Queensland and a Bachelor in Banking and Finance from the Queensland University of Technology, Australia.

Ivanna Salehudin | Member, Board of Directors

 

Ms Salehudin joined the board of Nova Satra Dx in 2016. She currently serves as Joint Managing Director at Nova Satra Holdings Sdn Bhd. Founded by Dato’ Salehudin Ngah in 1994, Nova Satra Holdings Sdn Bhd is a Family Investment Office with a diversified investment portfolio focused on South East Asia. Nova Satra Holdings’ investments comprise of real estate, trading and agencies representing companies such as De La Rue, Alcatel-Lucent, SAP and MIKOH. Ms Salehudin began her career as investment analyst with Sydney-based Babcock and Brown, a global investment and advisory firm.

 

Ms Salehudin holds a Bachelor of International Business from Bond University, Australia and obtained a Master of Finance from University of Technology, Sydney.

Kong Han Tan | Member, Board of Directors

 

Mr Kong Han Tan joined the board of Nova Satra Dx in 2016. Mr Tan is Chief Operating Officer of Genting Berhad and Deputy Chief Executive Officer at Genting Plantations Berhad. Mr. Tan has extensive experience in Investment Banking, leisure, gaming, real estate and medical technologies. He is also a Director of Singapore based Alzheimers disease research company TauRx Pharmaceuticals, UK based next generation sequencing company DNAe Group and U.S based Elevance Renewable Sciences.

 

Mr Tan holds a Bachelor of Arts in Economics and Law from Cambridge. He was called to the English Bar (Lincoln’s Inn) in 1989 and the Malaysian Bar in 1990.

Lee Sian Goh, MBA | Member, Board of Directors

 

Ms Lee Sian Goh joined the board of Nova Satra Dx in 2016. Ms Goh is Senior Vice President of Legal at Genting Berhad. Prior to joining Genting, she served as the in-house legal counsel for Maxis Communications Berahd. Ms Goh holds over 25 years’ experience in legal practice and was called to the Malaysian Bar in 1987. Ms. Goh is also Director of San Diego-based Applied Proteomics Inc.

 

Ms Goh holds a Bachelor of Economics and Bachelor of Law from Monash University Australia and a Master of Business Administration from the University of Central Florida.

Board of Advisors

Wen-son Hsieh, MD 

 

Dr Wen-son Hsieh joined the board of Nova Satra Dx in 2016. Dr Hsieh is a Medical Oncologist and serves as an Assistant Professor at Johns Hopkins University, and Principal Associate at the Cancer Sciences Institute of Singapore at the National University of Singapore. He specialises in the treatment of various types of cancers and is active in developing novel cancer diagnostics and molecularly targeted anti-cancer treatments. After studying Philosophy and Psychology at Oxford University on a prestigious Rhodes Scholarship, Dr Hsieh completed his medical training at Johns Hopkins University and Duke University.

 

With a research interest in molecularly targeted cancer therapies, immunotherapy and molecular diagnostics, Dr Hsieh has led a number of international studies involving centres in Singapore, Hong Kong, Korea, the Philippines, Myanmar and the United States examining novel treatments and novel diagnostic tests for nasopharyngeal and hepatocellular carcinoma.

 

He is also currently the principal investigator of more than ten active clinical trials investigating novel treatments for a variety of cancers. Dr Hsieh has authored over 80 scientific articles, abstracts, and book chapters and has lectured extensively at regional and international medical and scientific conferences.

 

Dr Hsieh obtained his Medical Degree from Johns Hopkins University, completed his Internal Medicine Residency at Duke University and his Medical Oncology Fellowship at Johns Hopkins University. Dr Hsieh is Diplomate to the American Board of Internal Medicine, Internal Medicine and Medical Oncology.

Dr Billy Chan 

 

Dr Billy Chan is President of AceCGT Group, a Hong Kong based company focused on life science technology for human health and wellness. Dr Chan was previously a Director at W&H Consultancy Company, where he provided business consulting services to companies in the medical and advanced medical technology sectors.

 

Prior to that, Dr Chan was President of DiagCor Bioscience Inc. After holding multiple management and operational roles, he oversaw the company’s molecular diagnostic business.

 

Dr Chan has a PhD in Development Biology and Embryology from the Chinese University of Hong Kong. He has a Masters in Medical Genetics from Brunel University, and a MBA from the University of Leicester.

Weng Wah Lee 

 

Mr Weng Wah Lee has over 15 years of experience in the fields of bioinformatics, molecular biology and high-performance computing cluster. In August 2017, he joined Genting Group to spearhead the establishment of high throughput DNA sequencing and Bioinformatics capabilities in genome sequencing, assembly and annotation. Weng Wah was actively involved in various oil palm and microbial genomics project and embarking his interest in human genomics. He specialises in the areas of biomarker discovery, metagenomics, assay development and parallel computing; he is also instrumental in genomics big data project.

 

Mr Lee earned his first degree in Resource Biotechnology from Universiti Malaysia Sarawak and obtained his MSc in Genetic Engineering and Molecular Biology from Universiti Putra Malaysia.